PMC:3245220 / 661-859 JSONTXT

{"project":"bionlp-st-ge-2016-uniprot","denotations":[{"id":"T451","span":{"begin":46,"end":50},"obj":"P17252"},{"id":"T452","span":{"begin":108,"end":112},"obj":"P17252"},{"id":"T453","span":{"begin":128,"end":132},"obj":"P17252"},{"id":"T454","span":{"begin":177,"end":182},"obj":"P09603"},{"id":"T455","span":{"begin":179,"end":182},"obj":"P04141"}],"namespaces":[{"prefix":"_base","uri":"http://www.uniprot.org/uniprot/"}],"text":" (PKC) inhibitor Ro-31-8220, the conventional PKCα/β inhibitor Gö-6976, overexpression of dominant negative PKCα constructs and PKCα siRNA reduced NF-κB activity in response to M-CSF. Interestingly,"}

{"project":"bionlp-st-ge-2016-reference","denotations":[{"id":"T468","span":{"begin":53,"end":62},"obj":"Negative_regulation"},{"id":"T469","span":{"begin":53,"end":62},"obj":"Negative_regulation"},{"id":"T470","span":{"begin":72,"end":86},"obj":"Gene_expression"},{"id":"T480","span":{"begin":46,"end":50},"obj":"Protein"},{"id":"T487","span":{"begin":177,"end":182},"obj":"Protein"},{"id":"T491","span":{"begin":51,"end":52},"obj":"Protein"},{"id":"T494","span":{"begin":90,"end":112},"obj":"Protein"},{"id":"T495","span":{"begin":128,"end":138},"obj":"Protein"}],"relations":[{"id":"R411","pred":"themeOf","subj":"T480","obj":"T468"},{"id":"R415","pred":"themeOf","subj":"T491","obj":"T469"},{"id":"R417","pred":"themeOf","subj":"T494","obj":"T470"}],"namespaces":[{"prefix":"_base","uri":"http://bionlp.dbcls.jp/ontology/ge.owl#"}],"text":" (PKC) inhibitor Ro-31-8220, the conventional PKCα/β inhibitor Gö-6976, overexpression of dominant negative PKCα constructs and PKCα siRNA reduced NF-κB activity in response to M-CSF. Interestingly,"}

{"project":"bionlp-st-ge-2016-reference-tees","denotations":[{"id":"T748","span":{"begin":2,"end":5},"obj":"Protein"},{"id":"T749","span":{"begin":46,"end":52},"obj":"Protein"},{"id":"T750","span":{"begin":90,"end":123},"obj":"Protein"},{"id":"T751","span":{"begin":128,"end":146},"obj":"Protein"},{"id":"T752","span":{"begin":147,"end":152},"obj":"Protein"},{"id":"T753","span":{"begin":177,"end":182},"obj":"Protein"},{"id":"T754","span":{"begin":72,"end":86},"obj":"Gene_expression"},{"id":"T755","span":{"begin":72,"end":86},"obj":"Gene_expression"},{"id":"T756","span":{"begin":72,"end":86},"obj":"Gene_expression"},{"id":"T757","span":{"begin":72,"end":86},"obj":"Gene_expression"},{"id":"T758","span":{"begin":165,"end":173},"obj":"Positive_regulation"},{"id":"T759","span":{"begin":165,"end":173},"obj":"Positive_regulation"},{"id":"T760","span":{"begin":165,"end":173},"obj":"Positive_regulation"},{"id":"T761","span":{"begin":165,"end":173},"obj":"Positive_regulation"},{"id":"T762","span":{"begin":165,"end":173},"obj":"Positive_regulation"}],"relations":[{"id":"R526","pred":"themeOf","subj":"T748","obj":"T755"},{"id":"R527","pred":"themeOf","subj":"T750","obj":"T756"},{"id":"R528","pred":"themeOf","subj":"T751","obj":"T757"},{"id":"R529","pred":"causeOf","subj":"T751","obj":"T758"},{"id":"R530","pred":"causeOf","subj":"T751","obj":"T759"},{"id":"R531","pred":"causeOf","subj":"T751","obj":"T760"},{"id":"R532","pred":"causeOf","subj":"T751","obj":"T761"},{"id":"R533","pred":"causeOf","subj":"T751","obj":"T762"},{"id":"R534","pred":"themeOf","subj":"T753","obj":"T758"},{"id":"R535","pred":"themeOf","subj":"T754","obj":"T759"},{"id":"R536","pred":"themeOf","subj":"T755","obj":"T760"},{"id":"R537","pred":"themeOf","subj":"T756","obj":"T761"},{"id":"R538","pred":"themeOf","subj":"T757","obj":"T762"}],"text":" (PKC) inhibitor Ro-31-8220, the conventional PKCα/β inhibitor Gö-6976, overexpression of dominant negative PKCα constructs and PKCα siRNA reduced NF-κB activity in response to M-CSF. Interestingly,"}

{"project":"events-check-again","denotations":[{"id":"T705","span":{"begin":46,"end":50},"obj":"Protein"},{"id":"T706","span":{"begin":51,"end":52},"obj":"Protein"},{"id":"T707","span":{"begin":53,"end":62},"obj":"Negative_regulation"},{"id":"T708","span":{"begin":53,"end":62},"obj":"Negative_regulation"},{"id":"T709","span":{"begin":72,"end":86},"obj":"Gene_expression"},{"id":"T710","span":{"begin":90,"end":112},"obj":"Protein"},{"id":"T711","span":{"begin":128,"end":138},"obj":"Protein"},{"id":"T712","span":{"begin":177,"end":182},"obj":"Protein"}],"relations":[{"id":"R501","pred":"themeOf","subj":"T705","obj":"T707"},{"id":"R502","pred":"themeOf","subj":"T706","obj":"T708"},{"id":"R503","pred":"themeOf","subj":"T710","obj":"T709"}],"text":" (PKC) inhibitor Ro-31-8220, the conventional PKCα/β inhibitor Gö-6976, overexpression of dominant negative PKCα constructs and PKCα siRNA reduced NF-κB activity in response to M-CSF. Interestingly,"}

{"project":"GO-MF","denotations":[{"id":"T528","span":{"begin":2,"end":5},"obj":"http://purl.obolibrary.org/obo/GO_0004697"},{"id":"T529","span":{"begin":46,"end":50},"obj":"http://purl.obolibrary.org/obo/GO_0004697"},{"id":"T530","span":{"begin":108,"end":112},"obj":"http://purl.obolibrary.org/obo/GO_0004697"},{"id":"T531","span":{"begin":128,"end":132},"obj":"http://purl.obolibrary.org/obo/GO_0004697"}],"text":" (PKC) inhibitor Ro-31-8220, the conventional PKCα/β inhibitor Gö-6976, overexpression of dominant negative PKCα constructs and PKCα siRNA reduced NF-κB activity in response to M-CSF. Interestingly,"}

{"project":"GO-BP","denotations":[{"id":"T515","span":{"begin":2,"end":5},"obj":"http://purl.obolibrary.org/obo/GO_0004697"},{"id":"T516","span":{"begin":46,"end":50},"obj":"http://purl.obolibrary.org/obo/GO_0004697"},{"id":"T517","span":{"begin":108,"end":112},"obj":"http://purl.obolibrary.org/obo/GO_0004697"},{"id":"T518","span":{"begin":128,"end":132},"obj":"http://purl.obolibrary.org/obo/GO_0004697"},{"id":"T520","span":{"begin":153,"end":173},"obj":"http://purl.obolibrary.org/obo/GO_0014823"},{"id":"T521","span":{"begin":165,"end":182},"obj":"http://purl.obolibrary.org/obo/GO_1903969"},{"id":"T522","span":{"begin":165,"end":182},"obj":"http://purl.obolibrary.org/obo/GO_0036005"},{"id":"T523","span":{"begin":165,"end":182},"obj":"http://purl.obolibrary.org/obo/GO_1903970"},{"id":"T524","span":{"begin":165,"end":182},"obj":"http://purl.obolibrary.org/obo/GO_1903971"}],"text":" (PKC) inhibitor Ro-31-8220, the conventional PKCα/β inhibitor Gö-6976, overexpression of dominant negative PKCα constructs and PKCα siRNA reduced NF-κB activity in response to M-CSF. Interestingly,"}

{"project":"pmc-enju-pas","denotations":[{"id":"T342","span":{"begin":1,"end":2},"obj":"-LRB-"},{"id":"T343","span":{"begin":2,"end":5},"obj":"NN"},{"id":"T344","span":{"begin":5,"end":6},"obj":"-RRB-"},{"id":"T345","span":{"begin":7,"end":16},"obj":"NN"},{"id":"T346","span":{"begin":17,"end":27},"obj":"NN"},{"id":"T347","span":{"begin":27,"end":28},"obj":"-COMMA-"},{"id":"T348","span":{"begin":29,"end":32},"obj":"DT"},{"id":"T349","span":{"begin":33,"end":45},"obj":"JJ"},{"id":"T350","span":{"begin":46,"end":52},"obj":"NN"},{"id":"T351","span":{"begin":53,"end":62},"obj":"NN"},{"id":"T352","span":{"begin":63,"end":70},"obj":"NN"},{"id":"T353","span":{"begin":70,"end":71},"obj":"-COMMA-"},{"id":"T354","span":{"begin":72,"end":86},"obj":"NN"},{"id":"T355","span":{"begin":87,"end":89},"obj":"IN"},{"id":"T356","span":{"begin":90,"end":98},"obj":"JJ"},{"id":"T357","span":{"begin":99,"end":107},"obj":"JJ"},{"id":"T358","span":{"begin":108,"end":112},"obj":"NN"},{"id":"T359","span":{"begin":113,"end":123},"obj":"NN"},{"id":"T360","span":{"begin":124,"end":127},"obj":"CC"},{"id":"T361","span":{"begin":128,"end":132},"obj":"NN"},{"id":"T362","span":{"begin":133,"end":138},"obj":"NN"},{"id":"T363","span":{"begin":139,"end":146},"obj":"VB"},{"id":"T364","span":{"begin":147,"end":152},"obj":"NN"},{"id":"T365","span":{"begin":153,"end":161},"obj":"NN"},{"id":"T366","span":{"begin":162,"end":164},"obj":"IN"},{"id":"T367","span":{"begin":165,"end":173},"obj":"NN"},{"id":"T368","span":{"begin":174,"end":176},"obj":"TO"},{"id":"T369","span":{"begin":177,"end":182},"obj":"NN"},{"id":"T370","span":{"begin":184,"end":197},"obj":"RB"},{"id":"T371","span":{"begin":197,"end":198},"obj":"-COMMA-"}],"relations":[{"id":"R306","pred":"arg2Of","subj":"T343","obj":"T342"},{"id":"R307","pred":"arg3Of","subj":"T344","obj":"T342"},{"id":"R310","pred":"arg1Of","subj":"T346","obj":"T345"},{"id":"R311","pred":"arg1Of","subj":"T346","obj":"T347"},{"id":"R312","pred":"arg1Of","subj":"T346","obj":"T353"},{"id":"R313","pred":"arg2Of","subj":"T352","obj":"T347"},{"id":"R314","pred":"arg1Of","subj":"T352","obj":"T348"},{"id":"R315","pred":"arg1Of","subj":"T352","obj":"T349"},{"id":"R316","pred":"arg1Of","subj":"T352","obj":"T350"},{"id":"R317","pred":"arg1Of","subj":"T352","obj":"T351"},{"id":"R318","pred":"arg1Of","subj":"T353","obj":"T360"},{"id":"R319","pred":"arg2Of","subj":"T354","obj":"T353"},{"id":"R320","pred":"arg1Of","subj":"T354","obj":"T355"},{"id":"R321","pred":"arg2Of","subj":"T359","obj":"T355"},{"id":"R322","pred":"arg1Of","subj":"T359","obj":"T356"},{"id":"R323","pred":"arg1Of","subj":"T359","obj":"T357"},{"id":"R324","pred":"arg1Of","subj":"T359","obj":"T358"},{"id":"R325","pred":"arg1Of","subj":"T360","obj":"T363"},{"id":"R326","pred":"arg2Of","subj":"T362","obj":"T360"},{"id":"R327","pred":"arg1Of","subj":"T362","obj":"T361"},{"id":"R328","pred":"arg1Of","subj":"T363","obj":"T366"},{"id":"R329","pred":"arg2Of","subj":"T365","obj":"T363"},{"id":"R330","pred":"arg1Of","subj":"T365","obj":"T364"},{"id":"R331","pred":"arg2Of","subj":"T367","obj":"T366"},{"id":"R332","pred":"arg1Of","subj":"T367","obj":"T368"},{"id":"R333","pred":"arg2Of","subj":"T369","obj":"T368"}],"namespaces":[{"prefix":"_base","uri":"http://kmcs.nii.ac.jp/enju/"}],"text":" (PKC) inhibitor Ro-31-8220, the conventional PKCα/β inhibitor Gö-6976, overexpression of dominant negative PKCα constructs and PKCα siRNA reduced NF-κB activity in response to M-CSF. Interestingly,"}

{"project":"bionlp-st-ge-2016-spacy-parsed","denotations":[{"id":"T150","span":{"begin":1,"end":2},"obj":"-LRB-"},{"id":"T151","span":{"begin":2,"end":5},"obj":"NNP"},{"id":"T152","span":{"begin":5,"end":6},"obj":"-RRB-"},{"id":"T153","span":{"begin":7,"end":16},"obj":"NN"},{"id":"T154","span":{"begin":17,"end":27},"obj":"NN"},{"id":"T155","span":{"begin":27,"end":28},"obj":","},{"id":"T156","span":{"begin":29,"end":32},"obj":"DT"},{"id":"T157","span":{"begin":33,"end":45},"obj":"JJ"},{"id":"T158","span":{"begin":46,"end":50},"obj":"NNP"},{"id":"T159","span":{"begin":50,"end":51},"obj":"NN"},{"id":"T160","span":{"begin":51,"end":52},"obj":"NN"},{"id":"T161","span":{"begin":53,"end":62},"obj":"NN"},{"id":"T162","span":{"begin":63,"end":70},"obj":"NNP"},{"id":"T163","span":{"begin":70,"end":71},"obj":","},{"id":"T164","span":{"begin":72,"end":86},"obj":"NN"},{"id":"T165","span":{"begin":87,"end":89},"obj":"IN"},{"id":"T166","span":{"begin":90,"end":98},"obj":"JJ"},{"id":"T167","span":{"begin":99,"end":107},"obj":"JJ"},{"id":"T168","span":{"begin":108,"end":112},"obj":"NNP"},{"id":"T169","span":{"begin":113,"end":123},"obj":"NNS"},{"id":"T170","span":{"begin":124,"end":127},"obj":"CC"},{"id":"T171","span":{"begin":128,"end":132},"obj":"NNP"},{"id":"T172","span":{"begin":133,"end":138},"obj":"NNP"},{"id":"T173","span":{"begin":139,"end":146},"obj":"VBD"},{"id":"T174","span":{"begin":147,"end":152},"obj":"JJ"},{"id":"T175","span":{"begin":153,"end":161},"obj":"NN"},{"id":"T176","span":{"begin":162,"end":164},"obj":"IN"},{"id":"T177","span":{"begin":165,"end":173},"obj":"NN"},{"id":"T178","span":{"begin":174,"end":176},"obj":"TO"},{"id":"T179","span":{"begin":177,"end":182},"obj":"NNP"},{"id":"T180","span":{"begin":182,"end":183},"obj":"."},{"id":"T181","span":{"begin":184,"end":197},"obj":"RB"},{"id":"T182","span":{"begin":197,"end":198},"obj":","}],"relations":[{"id":"R121","pred":"compound","subj":"T153","obj":"T154"},{"id":"R124","pred":"det","subj":"T156","obj":"T162"},{"id":"R125","pred":"amod","subj":"T157","obj":"T162"},{"id":"R126","pred":"compound","subj":"T158","obj":"T162"},{"id":"R127","pred":"compound","subj":"T159","obj":"T162"},{"id":"R128","pred":"compound","subj":"T160","obj":"T162"},{"id":"R129","pred":"compound","subj":"T161","obj":"T162"},{"id":"R131","pred":"punct","subj":"T163","obj":"T162"},{"id":"R132","pred":"appos","subj":"T164","obj":"T162"},{"id":"R133","pred":"prep","subj":"T165","obj":"T164"},{"id":"R134","pred":"amod","subj":"T166","obj":"T169"},{"id":"R135","pred":"amod","subj":"T167","obj":"T169"},{"id":"R136","pred":"compound","subj":"T168","obj":"T169"},{"id":"R137","pred":"pobj","subj":"T169","obj":"T165"},{"id":"R138","pred":"cc","subj":"T170","obj":"T169"},{"id":"R139","pred":"compound","subj":"T171","obj":"T172"},{"id":"R140","pred":"nsubj","subj":"T172","obj":"T173"},{"id":"R141","pred":"ROOT","subj":"T173","obj":"T173"},{"id":"R142","pred":"amod","subj":"T174","obj":"T175"},{"id":"R143","pred":"dobj","subj":"T175","obj":"T173"},{"id":"R144","pred":"prep","subj":"T176","obj":"T173"},{"id":"R145","pred":"pobj","subj":"T177","obj":"T176"},{"id":"R146","pred":"prep","subj":"T178","obj":"T177"},{"id":"R147","pred":"pobj","subj":"T179","obj":"T178"},{"id":"R148","pred":"punct","subj":"T180","obj":"T173"}],"text":" (PKC) inhibitor Ro-31-8220, the conventional PKCα/β inhibitor Gö-6976, overexpression of dominant negative PKCα constructs and PKCα siRNA reduced NF-κB activity in response to M-CSF. Interestingly,"}

{"project":"test2","denotations":[{"id":"T31","span":{"begin":46,"end":50},"obj":"Protein"},{"id":"T32","span":{"begin":51,"end":52},"obj":"Protein"},{"id":"T33","span":{"begin":53,"end":62},"obj":"Negative_regulation"},{"id":"T34","span":{"begin":90,"end":112},"obj":"Protein"},{"id":"T35","span":{"begin":128,"end":138},"obj":"Protein"},{"id":"T36","span":{"begin":177,"end":182},"obj":"Protein"}],"relations":[{"id":"R18","pred":"themeOf","subj":"T31","obj":"T33"},{"id":"R19","pred":"themeOf","subj":"T32","obj":"T33"}],"text":" (PKC) inhibitor Ro-31-8220, the conventional PKCα/β inhibitor Gö-6976, overexpression of dominant negative PKCα constructs and PKCα siRNA reduced NF-κB activity in response to M-CSF. Interestingly,"}